Trius Appoints Matthew Onaitis as General Counsel

Trius Appoints Matthew Onaitis as General Counsel

Industry Veteran Brings Legal, Transactional and Commercial Compliance
Expertise

SAN DIEGO, June 3, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc.
(Nasdaq:TSRX), a biopharmaceutical company focused on the discovery,
development and commercialization of innovative antibiotics for serious
infections, announced today Matthew Onaitis has been appointed to the newly
created role of General Counsel and Secretary. Mr. Onaitis was previously
Senior Vice President, General Counsel and Secretary of Somaxon
Pharmaceuticals, Inc. where he led the legal, compliance and business
development functions. Prior to his seven years at Somaxon, Mr. Onaitis served
as Associate General Counsel for the oncology strategic business unit of
Biogen Idec Inc. and as Director of Legal Affairs of Elan Corporation, plc.

"Matt has broad legal experience with both development-stage and
commercial-stage pharmaceutical companies," stated Jeffrey Stein, President
and CEO of Trius Therapeutics. "In particular, his background in completing
transactions, managing corporate governance and commercial compliance programs
and supporting regulatory and commercial operations will strengthen our
management team as we prepare for commercialization of tedizolid in the United
States, pending regulatory approval."

"I am excited to join Trius as the company prepares to file for regulatory
approval of tedizolid," stated Mr. Onaitis. "We are at a key juncture of
Trius' development as a company and I am pleased to be a part of its
leadership team as we advance to the next levels of value creation from
tedizolid and our pipeline programs."

About Trius Therapeutics

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of innovative antibiotics for
serious infections. The Company's lead investigational drug, tedizolid
phosphate, is a novel antibiotic in Phase 3 clinical development for the
treatment of serious gram-positive infections, including those caused by
methicillin-resistant Staphylococcus aureus (MRSA). Trius has partnered with
Bayer HealthCare for the development and commercialization of tedizolid
phosphate outside of the U.S., Canada and the European Union. In addition to
the Company's tedizolid phosphate clinical program, Trius has initiated
Investigational New Drug (IND) enabling studies for its Gyrase-B development
candidate with potent activity against Gram-negative bacterial pathogens
including multi-drug resistant strains of E. coli, Klebsiella, Acinetobacter
and Pseudomonas. For more information, visit www.triusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such statements are
subject to risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such statements
include, but are not limited to, statements regarding the anticipated effects
of the addition of Mr. Onaitis to the Company's management team and the
potential regulatory approval and commercialization of tedizolid. Risks that
contribute to the uncertain nature of the forward-looking statements include:
the accuracy of Trius' estimates regarding expenses, future revenues and
capital requirements; the success and timing of Trius' preclinical studies and
clinical trials; regulatory developments in the United States and foreign
countries; changes in Trius' plans to develop and commercialize its product
candidates; additional ongoing or planned clinical trials of tedizolid
phosphate may produce negative or inconclusive results; Trius may decide, or
the FDA may require Trius, to conduct additional clinical trials or to modify
Trius' ongoing clinical trials; Trius may experience delays in the
commencement, enrollment, completion or analysis of clinical testing for its
product candidates, or significant issues regarding the adequacy of its
clinical trial designs or the execution of its clinical trials, which could
result in increased costs and delays, or limit Trius' ability to obtain
regulatory approval; the third parties with whom Trius has partnered with for
the development of tedizolid phosphate and upon whom Trius relies to conduct
its clinical trials and manufacture its product candidates may not perform as
expected; tedizolid phosphate may not receive regulatory approval or be
successfully commercialized; unexpected adverse side effects or inadequate
therapeutic efficacy of tedizolid phosphate could delay or prevent regulatory
approval or commercialization; Trius' ability to obtain and maintain
intellectual property protection for its product candidates; and the loss of
key scientific or management personnel. These and other risks and
uncertainties are described more fully in Trius' most recent Form 10-K, Forms
10-Q and other documents filed with the United States Securities and Exchange
Commission, including those factors discussed under the caption "Risk Factors"
in such filings. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Trius undertakes no
obligation to update such statements to reflect events that occur or
circumstances that exist after the date on which they were made.

CONTACT: Public Relations Contact:
         Laura Kempke/Andrew Law at MSLGROUP
         trius@mslgroup.com
         781-684-0770
        
         Investor Relations Contact:
         Stefan Loren at Westwicke Partners, LLC
         sloren@westwicke.com
         443-213-0507
 
Press spacebar to pause and continue. Press esc to stop.